Please assess the completion status of the following clinical trial:

Trial Title: A Study for Patients With Multiple Sclerosis

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2/PHASE3
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~1. Subjects participating in this study must have completed treatment and all required evaluations in the previous MBP8298-01 study A Double Blind Placebo Controlled Multi-Centre Study to Evaluate the Efficacy and Safety of MBP8298 in Subjects with Secondary Progressive Multiple Sclerosis,~2. Subject must be able and willing to give meaningful, written informed consent prior to participation in the trial in accordance with regulatory requirements,~3. In the Investigator's opinion, subjects must be reliable, compliant and agree to cooperate with all trial evaluations.~Exclusion Criteria:~1. Use of any concomitant disease modifying therapy for Multiple Sclerosis e.g. ß-interferon, glatiramer acetate or mitoxantrone, cyclophosphamide, methotrexate, azathioprine, or any other immuno-modulating (e.g. IVIG) or immunosuppressive drugs including recombinant or non-recombinant cytokines.~2. Any medical, psychiatric or other condition that could result in a subject not being able to give fully informed consent, or to comply with the protocol requirements.~3. Any other condition that, in the Investigator's opinion, makes the subject unsuitable for participation in the study.~4. Females who are breast feeding, pregnant or not using a medically approved method of contraception regularly.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- Dirucotide (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).